Patents by Inventor Mark D. Lindner

Mark D. Lindner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
    Patent number: 6264941
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: July 24, 2001
    Assignee: Neurotech S.A.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
  • Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
    Patent number: 5908623
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: June 1, 1999
    Assignee: CytoTherapeutics, Inc.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
  • Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
    Patent number: 5676943
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: October 14, 1997
    Assignee: CytoTherapeutics, Inc.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
  • Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsules
    Patent number: 5656481
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 12, 1997
    Assignee: Cyto Therapeutics, Inc.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
  • Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsules
    Patent number: 5653975
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 5, 1997
    Assignee: CytoTherapeutics, Inc.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
  • Delivery of biologically active molecules using cells contained in biocompatible immunoisolatory capsules
    Patent number: 5639275
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: June 17, 1997
    Assignee: CytoTherapeutics, Inc.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich